How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study

Armando Tripodi, Lidia Padovan, Sophie Testa, Cristina Legnani, Veena Chantarangkul, Erica Scalambrino, Silvia Ludovici, Laura Bassi, Flora Peyvandi

Research output: Contribution to journalArticle

Abstract

Background: Apixaban is a newly developed direct oral anticoagulant targeting activated factor X (FXa). The degree of interference of apixaban with coagulation parameters has not been thoroughly investigated. Methods: Increasing amounts of apixaban were added to aliquots of a pooled normal plasma (PNP) to mimic a large range of concentrations (n=8) that are observed in treated patients. Upon preparation, samples were stored frozen and tested for a vast array of coagulation parameters (including procoagulant and anticoagulant factors) in three laboratories, using three widely used coagulation platforms (reagent/coagulometer combinations). Results: Results for each parameter were expressed as ratios of the value corresponding to each apixaban concentration to the value corresponding to the PNP without apixaban. By definition, ratios higher or lower than the unity define overestimation or underestimation, respectively. Prothrombin and activated partial thromboplastin times were barely prolonged by apixaban 200 ng/mL (ratios

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Volume53
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Keywords

  • antithrombin
  • antithrombotic drugs
  • coagulation factor assays
  • protein C
  • protein S
  • thrombosis

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Fingerprint Dive into the research topics of 'How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study'. Together they form a unique fingerprint.

  • Cite this